A case of psoriasis with IgA nephropathy successfully treated with secukinumab

International Journal of DermatologyEarly View Correspondence A case of psoriasis with IgA nephropathy successfully treated with secukinumab Sevgi Kulaklı MD, Corresponding Author Sevgi Kulaklı MD [email protected] orcid.org/0000-0001-7886-1060 Department of Dermatology and Venereology, Faculty of Medicine, Giresun University, Giresun, TurkeySearch for more papers by this authorTülin Akagün MD, Tülin Akagün MD orcid.org/0000-0003-2863-7882 Department of Internal Medicine, Division of Nephrology, Faculty of Medicine, Giresun University, Giresun, TurkeySearch for more papers by this author Sevgi Kulaklı MD, Corresponding Author Sevgi Kulaklı MD [email protected] orcid.org/0000-0001-7886-1060 Department of Dermatology and Venereology, Faculty of Medicine, Giresun University, Giresun, TurkeySearch for more papers by this authorTülin Akagün MD, Tülin Akagün MD orcid.org/0000-0003-2863-7882 Department of Internal Medicine, Division of Nephrology, Faculty of Medicine, Giresun University, Giresun, TurkeySearch for more papers by this author First published: 11 November 2023 https://doi.org/10.1111/ijd.16903 Conflict of interest: None. Funding source: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Chiu HY, Huang HL, Li CH, Yin YJ, Chen HA, Hsu ST, et al. Increased risk of glomerulonephritis and chronic kidney disease in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. Br J Dermatol. 2015; 173(1): 146–154. 2Fala L. Cosentyx (secukinumab): first IL-17A antagonist receives FDA approval for moderate-to-severe plaque psoriasis. Am Health Drug Benefits. 2016; 9(Spec Feature): 60–63. 3Kluger N, Du-Thanh A, Bessis D, Servel MF, Mourad G. Psoriasis-associated IgA nephropathy under infliximab therapy. Int J Dermatol. 2015; 54(3): e79–e80. 4Sakellariou GT, Vounotrypidis P, Berberidis C. Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy. Clin Rheumatol. 2007; 26(7): 1132–1133. 5Dattola A, Zangrilli A, Bianchi L. Risankizumab for plaque and guttate psoriasis in a patient with IgA-related glomerulonephritis. Dermatol Pract Concept. 2021; 11(4):e2021100. 6Zhang L, Xue S, Yu J, Si H, Xu Y, Li J, et al. IgA nephropathy associated with erythrodermic psoriasis: a case report. Medicine (Baltimore). 2019; 98(19):e15433. 7Cao Z, Liu Z, Zhu X, Yang Q, Xu Q, Zhang C. Successful secukinumab treatment in focal segmental glomerulosclerosis associated with plaque psoriasis. Ren Fail. 2022; 44(1): 826–830. 8Ochi M, Toyama T, Ando M, Sato K, Kamikawa Y, Sagara A, et al. A case of secondary IgA nephropathy accompanied by psoriasis treated with secukinumab. CEN Case Rep. 2019; 8(3): 200–204. Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation